The immuno-oncology therapy developer has launched with $56m in series A funding from investors including Taiho Ventures and UPMC enterprises.
US-based cancer biotherapeutics developer Werewolf Therapeutics closed a $56m series A round yesterday featuring Taiho Ventures, the corporate venture capital vehicle for pharmaceutical company Taiho Pharmaceutical.
Healthcare investment firm MPM Capital and VC firm Longwood Fund co-led the round, which included UPMC Enterprises, the commercialisation arm of healthcare provider and insurer UPMC, in addition to Arkin Bio Ventures and DC Investment Partners.
Werewolf is developing cancer treatments using its Predator protein engineering platform that will work by stimulating the body’s…
